Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Persson

Showing results (511-520 of 517) with videos related to

Pageof 52
Sort By:
You have reached the last page of results.This site can display upto 517 results.
Molecular Cancer|November 1, 2024
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironmentChristina Sternberg, Martin Raigel, Tanja Limberger, et al.
Frontiers in Endocrinology|October 20, 2022
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancerAnna E Harris, Veronika M Metzler, Jennifer Lothion-Roy, et al.
Molecular Cancer|July 7, 2026
Correction: Cell‑autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53‑driven senescence and confers an immune‑active tumor microenvironmentChristina Sternberg, Martin Raigel, Tanja Limberger, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Cancer Research|May 17, 2023
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline GliomaEvangeline R Jackson, Ryan J Duchatel, Dilana E Staudt, et al.
Cancer Research|May 5, 2023
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline gliomaEvangeline R Jackson, Ryan J Duchatel, Dilana E Staudt, et al.
The Journal of Clinical Investigation|February 6, 2024
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine gliomaRyan J Duchatel, Evangeline R Jackson, Sarah G Parackal, et al.
Pageof 52

Showing results (511-520 of 517) with videos related to

Sort By:
Pageof 52
You have reached the last page of results.This site can display upto 517 results.
Molecular Cancer|November 1, 2024
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironmentChristina Sternberg, Martin Raigel, Tanja Limberger, et al.
Frontiers in Endocrinology|October 20, 2022
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancerAnna E Harris, Veronika M Metzler, Jennifer Lothion-Roy, et al.
Molecular Cancer|July 7, 2026
Correction: Cell‑autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53‑driven senescence and confers an immune‑active tumor microenvironmentChristina Sternberg, Martin Raigel, Tanja Limberger, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Cancer Research|May 17, 2023
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline GliomaEvangeline R Jackson, Ryan J Duchatel, Dilana E Staudt, et al.
Cancer Research|May 5, 2023
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline gliomaEvangeline R Jackson, Ryan J Duchatel, Dilana E Staudt, et al.
The Journal of Clinical Investigation|February 6, 2024
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine gliomaRyan J Duchatel, Evangeline R Jackson, Sarah G Parackal, et al.
Pageof 52